Biogen Investors Face Next Test With Pending Drug Patent Ruling

(Bloomberg) -- Biogen Inc. investors should strap themselves in for a volatile week ahead of a key patent decision on its blockbuster multiple sclerosis drug.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.